Inclusion Criteria:

- Patients with histologically confirmed metastatic, unresectable bone or soft tissue
sarcomas who had past treatment with anthracycline and/or ifosfamide to which the
disease was primarily refractory or progressed after initial response.

- Any of above drugs is allowed to be used as adjuvant treatment.

- Unidimensionally measurable disease

- 3 or less than prior chemotherapies

- Age 17 years old or older

- ECOG performance status 2 or less, Life expectancy 6 month or less

- Adequate bone marrow, liver, kidney, and cardiac function

- Written informed consent

Exclusion Criteria:

- Pregnant or lactating patients

- Patients with resectable metastasis

- Patients with history of CNS metastasis

- Gastrointestinal stromal tumors, chondrosarcoma, neuroblastoma

- Hypersensitivity to the active substance, to other rapamycin derivatives, or to any
of the excipients.

- Any preexisting medical condition of sufficient severity to prevent full compliance
with the study